Logo

Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

Share this

Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

Shots:

  • Tecentriq (atezolizumab- q2w) Intravenous Infusion 840mg has been listed on the NIH reimbursement price list and launched by Chugai as an optimal formulation to treat PD-L1-positive hormone receptor-negative and HER2-negative inoperable or recurrent BC
  • The P-III IMpassion130 study involve assessing of Tecentriq + nab-paclitaxel (albumin-bound) vs nab-paclitaxel (albumin-bound) in patients with unresectable LA/metastatic TNBC prior not treated with systemic therapy for mBC
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1receptors and has received MHLW’s approval for this indication and dosage form on Sep 20- 2019

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical | Image: Business Insider


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions